Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-09-05
2008-10-28
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000
Reexamination Certificate
active
07442680
ABSTRACT:
Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5846937 (1998-12-01), Drucker
patent: WO 98/05351 (1998-02-01), None
patent: WO 99/07404 (1999-02-01), None
Schinzel R, et al, The Phosphate recognition site ofEscherichia colimaltodextrin phophsorylase, FEBS (1991) vol. 286, pp. 125-128.
Barragán et al., “Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats”,Regulatory Peptides, 67:63-68 (1996).
Bhavsar et al., “Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents”,Soc. Neurosci. Abstr., 21:460 (188.8) (1995).
D'Alessio et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons”,J. Clin. Invest., 97(1):133-138 (1996).
Edwards et al., “Cardiovascular and Pancreatic Endocrine Responses to Glucagon-Like Peptide-1(7-36) Amide in the Conscious Calf”,Exp. Physiol., 82:709-716 (1997).
Eissele et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide”,Life Sci., 55(8):629-634 (1994).
Eng et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom”,J. Biol. Chem., 265(33):20259-20262 (1990).
Eng et al., “Isolation and Characterization of Exendin-4, and Exendin-3 Analogue, fromHeloderma suspectumVenom”,J. Biol. Chem., 267(11):7402-7405 (1992).
Fehmann et al., “Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-1(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39)”,Peptides, 15(3):453-456 (1994).
Ferguson et al., “Cell-Surface Anchoring of Proteins via Glycosylphosphatidylinositol Structures”,Annu. Rev. Biochem., 57:285-320 (1988).
Göke et al., “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells”,J. Biol. Chem., 268(26):19650-19655 (1993).
Knudsen et al., “Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration”,J. Med. Chem., 43:1664-1669 (2000).
Kolligs et al., “Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide”,Diabetes, 44:16-19 (1995).
Malhotra et al., “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides, 41:149-156 (1992).
Montrose-Rafizadeh et al., “Structure-function Analysis of Exendin-4 / GLP-1 Analogs”,Diabetes, 45(Suppl. 2):152A (1996).
O'Halloran et al., “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man”,Journal of Endocrinology, 126:169-173 (1990).
Ørskov et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable”,Diabetes, 42:658-661 (1993).
Raufman et al., “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem., 266(5):2897-2902 (1991).
Raufman et al., “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem., 267(30):21432-21437 (1992).
Schepp et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2”,Eur. J. Pharm., 269:183-191 (1994).
Schjoldager et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans”,Digestive Disease and Sciences, 34(5):703-708 (1989).
Singh et al., “Use of125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig”,Regulatory Peptides, 53:47-59 (1994).
Tang-Christensen et al., “Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats”,Am. J. Physiol., 271:R848-R856 (1996).
Thorens et al., “Expression cloning of the Pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1”,Proc. Natl. Acad. Sci. USA, 88:8641-8645 (1992).
Thorens et al., “Cloning and Functional Expression of the Human Islet GLP-1 Receptor”,Diabetes, 42:1678-1682 (1993).
Turton et al., “A role for glucagon-like peptide-1 in the central regulation of feeding”,Nature, 379:69-72 (1996).
Wang et al., “Glucagon-like Peptide-1 is a Physiological Incretin in Rat”,J. Clin. Invest., 95:417-421 (1995).
Wettergren et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man”,Digestive Diseases and Sciences, 38(4):665-673 (1993).
Willms et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients”,J. Clin. Endocrinol. Metab., 81(1):327-332 (1996).
Young et al., “Preclinical Pharmacology of Pramlintide in the Rat: Comparisons with Human and Rat Amylin”,Drug Development Research, 37:231-248 (1996).
Beeley Nigel R. A.
Prickett Kathryn
Vine Will
Young Andrew A.
Amylin Pharmaceuticals Inc.
Bradley Christina Marchetti
Tsang Cecilia
LandOfFree
Inotropic and diuretic effects of GLP-1 and GLP-1 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inotropic and diuretic effects of GLP-1 and GLP-1 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inotropic and diuretic effects of GLP-1 and GLP-1 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4011127